WallStSmart
DAWN

Day One Biopharmaceuticals Inc

NASDAQ: DAWN · HEALTHCARE · BIOTECHNOLOGY

$21.53
+0.00% today

Updated 2026-04-23

Market cap
$2.22B
P/E ratio
P/S ratio
14.06x
EPS (TTM)
$-1.04
Dividend yield
52W range
$6 – $22
Volume
4.5M

Day One Biopharmaceuticals Inc (DAWN) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+14.9%
Last 4 quarters
Revenue YoY growth
+83.9%
Most recent quarter
EPS YoY growth
+66.7%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+9.2%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+25.0%
2025-11-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-24$-0.21-8.8%$11.70$10.93-6.6%
2025-11-04$-0.19+34.5%$7.31$9.14+25.0%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.19$-0.21-8.8%$53.72M+83.9%
2025-09-30$-0.29$-0.19+34.5%$39.80M-57.6%
2025-06-30$-0.35$-0.29+17.4%$33.91M+313.9%
2025-03-31$-0.42$-0.35+16.7%$30.76M
2024-12-31$-0.46$-0.63-36.2%$29.21M+5115.7%
2024-09-30$-0.32$0.38+220.4%$93.76M
2024-06-30$-0.75$-0.05+93.3%$8.19M
2024-03-31$-0.66$-0.72-9.1%
2023-12-31$-0.58$-0.64-10.3%$560000.00
2023-09-30$-0.60$-0.54+10.0%
2023-06-30$-0.61$-0.61+0.0%
2023-03-31$-0.59$-0.59+0.0%

Frequently asked questions

Has Day One Biopharmaceuticals Inc beaten earnings estimates?
Day One Biopharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +14.9% over the last 4 quarters.
How does DAWN stock react to earnings?
DAWN stock has moved an average of +9.2% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Day One Biopharmaceuticals Inc's revenue growth rate?
Day One Biopharmaceuticals Inc reported year-over-year revenue growth of +83.9% in its most recent quarter, with EPS growing +66.7% year-over-year.